305 related articles for article (PubMed ID: 22065157)
1. Midregional proadrenomedullin for prediction of cardiovascular events in coronary artery disease: results from the AtheroGene study.
Wild PS; Schnabel RB; Lubos E; Zeller T; Sinning CR; Keller T; Tzikas S; Lackner KJ; Peetz D; Rupprecht HJ; Bickel C; Morgenthaler NG; Papassotiriou J; Tiret L; Münzel T; Blankenberg S
Clin Chem; 2012 Jan; 58(1):226-36. PubMed ID: 22065157
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular Mortality in Chest Pain Patients: Comparison of Natriuretic Peptides With Novel Biomarkers of Cardiovascular Stress.
Sinning C; Ojeda F; Zeller T; Zengin E; Rupprecht HJ; Lackner KJ; Bickel C; Blankenberg S; Schnabel RB; Westermann D
Can J Cardiol; 2016 Dec; 32(12):1470-1477. PubMed ID: 27568502
[TBL] [Abstract][Full Text] [Related]
3. Midregional proadrenomedullin (MR-proADM) in the risk stratification of patients with acute pulmonary embolism.
Pedowska-Włoszek J; Kostrubiec M; Kurnicka K; Ciurzynski M; Palczewski P; Pruszczyk P
Thromb Res; 2013 Nov; 132(5):506-10. PubMed ID: 24060192
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of plasma MR-proADM vs NT-proBNP for heart failure in people with type 2 diabetes: the SURDIAGENE prospective study.
Fraty M; Velho G; Gand E; Fumeron F; Ragot S; Sosner P; Mohammedi K; Gellen B; Saulnier PJ; Halimi JM; Montaigne D; Ducrocq G; Rehman M; Marre M; Roussel R; Hadjadj S;
Diabetologia; 2018 Dec; 61(12):2643-2653. PubMed ID: 30232509
[TBL] [Abstract][Full Text] [Related]
5. Pro-A-type natriuretic peptide, proadrenomedullin, and N-terminal pro-B-type natriuretic peptide used in a multimarker strategy in primary health care in risk assessment of patients with symptoms of heart failure.
Alehagen U; Dahlström U; Rehfeld JF; Goetze JP
J Card Fail; 2013 Jan; 19(1):31-9. PubMed ID: 23273592
[TBL] [Abstract][Full Text] [Related]
6. Midregional proadrenomedullin and growth differentiation factor-15 are not influenced by obesity in heart failure patients.
Sinning C; Ojeda F; Wild PS; Schnabel RB; Schwarzl M; Ohdah S; Lackner KJ; Pfeiffer N; Michal M; Blettner M; Munzel T; Kempf T; Wollert KC; Kuulasmaa K; Blankenberg S; Salomaa V; Westermann D; Zeller T
Clin Res Cardiol; 2017 Jun; 106(6):401-410. PubMed ID: 28004184
[TBL] [Abstract][Full Text] [Related]
7. Association of midregional proadrenomedullin with coronary artery stenoses, soft atherosclerotic plaques and coronary artery calcium.
Roos M; Schuster T; Ndrepepa G; Baumann M; Lutz J; Braun S; Martinof S; Schömig A; Heemann U; Kastrati A; Hausleiter J
Heart Vessels; 2012 Jul; 27(4):352-9. PubMed ID: 21725669
[TBL] [Abstract][Full Text] [Related]
8. Comparison of long-term prognostic value of N-terminal-proBNP and midregional-pro-adrenomedullin in patients with acute myocardial infarction.
Walter T; Brueckmann M; Lang S; Sauer T; Fiedler E; Papassotiriou J; Behnes M; Elmas E; Borggrefe M; Bertsch T
Clin Lab; 2010; 56(7-8):303-9. PubMed ID: 20857894
[TBL] [Abstract][Full Text] [Related]
9. Mid-regional pro-adrenomedullin in patients with acute dyspnea: Data from the Akershus Cardiac Examination (ACE) 2 Study.
Pervez MO; Lyngbakken MN; Myhre PL; Brynildsen J; Langsjøen EC; Høiseth AD; Christensen G; Omland T; Røsjø H
Clin Biochem; 2017 May; 50(7-8):394-400. PubMed ID: 28065681
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) study.
Khan SQ; O'Brien RJ; Struck J; Quinn P; Morgenthaler N; Squire I; Davies J; Bergmann A; Ng LL
J Am Coll Cardiol; 2007 Apr; 49(14):1525-32. PubMed ID: 17418290
[TBL] [Abstract][Full Text] [Related]
11. Midregional proadrenomedullin and its change predicts recurrent major coronary events and heart failure in stable coronary heart disease patients: the LIPID study.
Funke-Kaiser A; Mann K; Colquhoun D; Zeller T; Hunt D; Simes J; Sullivan D; Sydow K; West M; White H; Blankenberg S; Tonkin AM;
Int J Cardiol; 2014 Mar; 172(2):411-8. PubMed ID: 24508492
[TBL] [Abstract][Full Text] [Related]
12. Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea.
Shah RV; Truong QA; Gaggin HK; Pfannkuche J; Hartmann O; Januzzi JL
Eur Heart J; 2012 Sep; 33(17):2197-205. PubMed ID: 22645194
[TBL] [Abstract][Full Text] [Related]
13. MR-proADM Predicts Exercise Capacity and Survival Superior to Other Biomarkers in PH.
Kolditz M; Seyfarth HJ; Wilkens H; Ewert R; Bollmann T; Dinter C; Hertel S; Klose H; Opitz C; Grünig E; Höffken G; Halank M
Lung; 2015 Dec; 193(6):901-10. PubMed ID: 26363916
[TBL] [Abstract][Full Text] [Related]
14. Prognostic potential of midregional pro-adrenomedullin following decompensation for systolic heart failure: comparison with cardiac natriuretic peptides.
Morbach C; Marx A; Kaspar M; Güder G; Brenner S; Feldmann C; Störk S; Vollert JO; Ertl G; Angermann CE;
Eur J Heart Fail; 2017 Sep; 19(9):1166-1175. PubMed ID: 28516504
[TBL] [Abstract][Full Text] [Related]
15. Association of MR-proadrenomedullin with cardiovascular risk factors and subclinical cardiovascular disease.
Neumann JT; Tzikas S; Funke-Kaiser A; Wilde S; Appelbaum S; Keller T; Ojeda-Echevarria F; Zeller T; Zwiener I; Sinning CR; Jagodzinski A; Schnabel RB; Lackner KJ; Münzel T; Blankenberg S; Wild PS; Sydow K
Atherosclerosis; 2013 Jun; 228(2):451-9. PubMed ID: 23562132
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of midregional pro-adrenomedullin compared to natriuretic peptides for incident cardiovascular disease and heart failure in the population-based FINRISK 1997 cohort.
Funke-Kaiser A; Havulinna AS; Zeller T; Appelbaum S; Jousilahti P; Vartiainen E; Blankenberg S; Sydow K; Salomaa V
Ann Med; 2014 May; 46(3):155-62. PubMed ID: 24506434
[TBL] [Abstract][Full Text] [Related]
17. Pro B-type Natriuretic Peptide and Midregional Proadrenomedullin are Associated with Incident Carotid Stenosis During Long Term Follow-up.
Fatemi S; Acosta S; Zarrouk M; Engström G; Melander O; Gottsäter A
J Stroke Cerebrovasc Dis; 2021 Jan; 30(1):105403. PubMed ID: 33160126
[TBL] [Abstract][Full Text] [Related]
18. Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis.
Palladini G; Barassi A; Perlini S; Milani P; Foli A; Russo P; Albertini R; Obici L; Lavatelli F; Sarais G; Casarini S; Moratti R; Melzi d'Eril GV; Merlini G
Amyloid; 2011 Dec; 18(4):216-21. PubMed ID: 22070520
[TBL] [Abstract][Full Text] [Related]
19. MR-proANP and MR-proADM for risk stratification of patients with acute chest pain.
Tzikas S; Keller T; Ojeda FM; Zeller T; Wild PS; Lubos E; Kunde J; Baldus S; Bickel C; Lackner KJ; Münzel TF; Blankenberg S
Heart; 2013 Mar; 99(6):388-95. PubMed ID: 23213173
[TBL] [Abstract][Full Text] [Related]
20. Midregional pro-adrenomedullin in addition to b-type natriuretic peptides in the risk stratification of patients with acute dyspnea: an observational study.
Potocki M; Breidthardt T; Reichlin T; Morgenthaler NG; Bergmann A; Noveanu M; Schaub N; Uthoff H; Freidank H; Buser L; Bingisser R; Christ M; Mebazaa A; Mueller C
Crit Care; 2009; 13(4):R122. PubMed ID: 19627611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
